<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04687475</url>
  </required_header>
  <id_info>
    <org_study_id>19-112</org_study_id>
    <nct_id>NCT04687475</nct_id>
  </id_info>
  <brief_title>Implementation of a Clinical Tool to Improve Waitlist Mortality in Patients With Cystic Fibrosis</brief_title>
  <official_title>Implementation of a Clinical Tool to Improve Waitlist Mortality in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Implementation of a Clinical Tool to Improve Waitlist Mortality in Patients With Cystic&#xD;
      Fibrosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this project is to implement a clinical tool utilizing predictors of mortality for&#xD;
      patients with Cystic Fibrosis (CF) on the waiting list to identify candidates that should&#xD;
      present for urgent medical care and, if appropriate, will prompt clinicians to update a&#xD;
      candidate's lung allocation score (LAS), the score used to prioritize lung transplant&#xD;
      candidates for transplant by medical urgency, and avoid undetected decline. The clinical tool&#xD;
      consists of home spirometry measures and patient reported outcomes that is completed weekly&#xD;
      on a mobile application device used clinically to track spirometry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung Allocation Score (LAS)</measure>
    <time_frame>Through study completion, an average of 3-6 months (time spent on the lung transplant waiting list).</time_frame>
    <description>Change in LAS value at the first clinic visit triggered by the clinical tool</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to transplant</measure>
    <time_frame>Through study completion, up to 1 year</time_frame>
    <description>Measured in days (time spent on the lung transplant waiting list)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival to transplant</measure>
    <time_frame>Through study completion, up to 1 year</time_frame>
    <description>Binary outcome measure to indicate if individual survived to transplant</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Lung Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>Clinical Tool (Mobile Spirometry and Survey)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects enrolled will be placed into the clinical tool arm. The clinical tool is comprised of a mobile application based assessment of home spirometry and a survey measuring patient reported outcomes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical Tool (Mobile Spirometry and Survey)</intervention_name>
    <description>The clinical tool is a combination of home spirometry measurements and a patient survey measuring patient reported outcomes including the Cystic Fibrosis Respiratory Symptom Diary (CFRSD) and Chronic Respiratory Infection Symptom Score (CRISSÂ©), with permission from the Seattle Quality of Life Group.</description>
    <arm_group_label>Clinical Tool (Mobile Spirometry and Survey)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Cystic Fibrosis&#xD;
&#xD;
          -  To be listed for lung transplant&#xD;
&#xD;
          -  Has purchased home spirometer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis other than Cystic Fibrosis&#xD;
&#xD;
          -  Unable to read&#xD;
&#xD;
          -  Unable to use computer or smartphone device to access mobile application&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carli J Lehr, MD, MS</last_name>
    <phone>216-444-0962</phone>
    <email>lehrc@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Weaver, BSN</last_name>
    <phone>216-445-6671</phone>
    <email>WEAVERD@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carli J Lehr, MD, MS</last_name>
      <phone>216-444-0962</phone>
      <email>lehrc@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>David Weaver, BSN</last_name>
      <phone>216-445-6671</phone>
      <email>weaverd@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Carli J Lehr, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maryam Valapour, MD, MPP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elliott Dasenbrook, MD, MHS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

